About all

Edluar vs Ambien: Comparing Sublingual and Oral Zolpidem for Insomnia Treatment

by alexxlab

How does sublingual zolpidem (Edluar) compare to oral zolpidem (Ambien) in treating insomnia. What are the differences in onset of action and sleep quality between these two formulations. How effective is sublingual zolpidem for initiating and maintaining sleep in patients with primary insomnia.

Содержание

Understanding Zolpidem: Sublingual vs Oral Formulations

Zolpidem is a widely prescribed medication for the treatment of insomnia. It belongs to a class of drugs known as sedative-hypnotics, which work by enhancing the effects of GABA, a neurotransmitter that promotes sleep. Two common formulations of zolpidem are available: sublingual (Edluar) and oral (Ambien). While both contain the same active ingredient, their routes of administration differ, potentially impacting their effectiveness and onset of action.

What is sublingual zolpidem (Edluar)?

Sublingual zolpidem, marketed under the brand name Edluar, is a formulation designed to be placed under the tongue where it dissolves and is absorbed directly into the bloodstream. This route of administration bypasses the digestive system, potentially leading to faster onset of action.

How does oral zolpidem (Ambien) work?

Oral zolpidem, commonly known as Ambien, is taken by mouth and swallowed. It is absorbed through the gastrointestinal tract, which may result in a slightly slower onset of action compared to the sublingual form.

Comparing Sleep Induction: Edluar vs Ambien

A randomized, double-blind, cross-over study published in Current Medical Research and Opinion in 2010 compared the hypnotic effects of sublingual zolpidem (Edluar) 10 mg to oral zolpidem (Ambien) 10 mg in patients with primary insomnia. The study focused on sleep induction parameters, including latency to persistent sleep (LPS), sleep onset latency (SOL), and latency to stage 1 sleep (ST1L).

How much faster does Edluar induce sleep compared to Ambien?

The study found that sublingual zolpidem significantly shortened LPS by 34% or 10.3 minutes compared to oral zolpidem. This difference was statistically significant, with a 95% confidence interval of -4.3 to -16.2 minutes (p = 0.001). Additionally, both SOL and ST1L were significantly reduced with sublingual zolpidem (p < 0.01).

Does the faster onset of action translate to better overall sleep?

While sublingual zolpidem demonstrated superior sleep-inducing properties, both formulations were comparable in terms of sleep maintenance. The study reported no significant difference in total sleep time (TST) between Edluar and Ambien.

Subjective Sleep Quality and Residual Effects

In addition to objective polysomnographic measurements, the study also assessed patients’ subjective experiences of sleep quality and any residual effects the following morning.

Do patients report better sleep with Edluar compared to Ambien?

Interestingly, despite the objective improvements in sleep onset with sublingual zolpidem, the study found no significant difference in subjective sleep quality between the two formulations. Patients reported similar levels of satisfaction with their sleep regardless of whether they took Edluar or Ambien.

Are there differences in next-day residual effects between the two formulations?

The study reported no significant differences in next-day residual effects between sublingual and oral zolpidem. This suggests that the faster onset of action with Edluar does not come at the cost of increased grogginess or impairment the following morning.

Safety and Tolerability of Sublingual vs Oral Zolpidem

When considering any medication, it’s crucial to evaluate its safety profile and potential side effects. The 2010 study provided insights into the tolerability of both zolpidem formulations.

How well-tolerated are Edluar and Ambien?

Both routes of administration were reported to be well-tolerated by the study participants. This suggests that the sublingual formulation does not introduce any significant new safety concerns compared to the well-established oral form.

Are there any specific side effects associated with sublingual zolpidem?

While the study did not report any unique side effects for the sublingual formulation, it’s important to note that all forms of zolpidem can potentially cause side effects such as dizziness, daytime drowsiness, and in rare cases, complex sleep behaviors. Patients should always consult with their healthcare provider about potential risks and side effects.

Clinical Implications of Faster Sleep Onset

The demonstrated superiority of sublingual zolpidem in reducing time to sleep onset has potential implications for clinical practice and patient care.

Who might benefit most from sublingual zolpidem?

Patients who struggle primarily with sleep initiation rather than sleep maintenance may find sublingual zolpidem particularly beneficial. The faster onset of action could be especially helpful for those who experience anxiety or frustration when trying to fall asleep.

Could sublingual zolpidem reduce overall medication exposure?

Given that sublingual zolpidem achieves faster sleep onset with the same dose as oral zolpidem, it’s possible that some patients might achieve satisfactory results with a lower overall dose. This could potentially reduce the risk of side effects and dependence, though further research would be needed to confirm this hypothesis.

Limitations and Future Research Directions

While the 2010 study provides valuable insights into the comparative efficacy of sublingual and oral zolpidem, there are some limitations to consider and areas for future research.

What are the long-term effects of sublingual zolpidem use?

The study focused on short-term use of zolpidem. Further research is needed to evaluate the long-term efficacy and safety of sublingual zolpidem compared to oral formulations, particularly in terms of tolerance development and potential for dependence.

How does sublingual zolpidem perform in diverse patient populations?

The study included a relatively homogeneous group of patients with primary insomnia. Future studies could explore the effectiveness of sublingual zolpidem in more diverse populations, including older adults, patients with comorbid conditions, and those with different subtypes of insomnia.

Practical Considerations for Patients and Healthcare Providers

When deciding between sublingual and oral zolpidem, there are several practical factors that patients and healthcare providers should consider.

Is sublingual zolpidem suitable for all patients?

While sublingual zolpidem offers advantages in terms of faster sleep onset, it may not be appropriate for all patients. Those with dry mouth conditions or difficulties with sublingual administration might prefer the oral formulation. Additionally, patients should be able to remain in bed for at least 7-8 hours after taking either form of zolpidem to avoid the risk of next-day impairment.

How do cost and availability factor into the decision?

Availability and cost can vary between sublingual and oral zolpidem formulations. Patients and healthcare providers should consider insurance coverage, out-of-pocket costs, and local availability when choosing between the two options.

  • Sublingual zolpidem (Edluar) may be more expensive than generic oral zolpidem
  • Insurance coverage may differ between formulations
  • Availability of sublingual zolpidem may be more limited in some areas

Alternative Treatments and Combination Approaches

While zolpidem is an effective treatment for many patients with insomnia, it’s important to consider it within the broader context of insomnia management.

What non-pharmacological approaches can complement zolpidem treatment?

Cognitive Behavioral Therapy for Insomnia (CBT-I) is considered a first-line treatment for chronic insomnia. It can be used alone or in combination with pharmacological treatments like zolpidem. Other non-pharmacological approaches include:

  • Sleep hygiene improvements
  • Relaxation techniques
  • Stimulus control therapy
  • Sleep restriction therapy

Are there other pharmacological alternatives to zolpidem?

While zolpidem is a popular choice for insomnia treatment, other options are available depending on the patient’s specific needs and medical history:

  1. Other non-benzodiazepine hypnotics (e.g., eszopiclone, zaleplon)
  2. Melatonin receptor agonists (e.g., ramelteon)
  3. Orexin receptor antagonists (e.g., suvorexant)
  4. Sedating antidepressants (e.g., trazodone, doxepin)

Healthcare providers should work with patients to determine the most appropriate treatment approach based on individual factors such as insomnia subtype, comorbid conditions, and patient preferences.

In conclusion, the comparative study of sublingual zolpidem (Edluar) and oral zolpidem (Ambien) reveals that the sublingual formulation offers significant advantages in terms of faster sleep onset without compromising overall sleep quality or safety. This makes it a potentially valuable option for patients struggling with sleep initiation. However, the choice between sublingual and oral zolpidem should be made on an individual basis, taking into account factors such as patient preferences, specific sleep complaints, and practical considerations like cost and availability. As with any insomnia treatment, zolpidem should be used as part of a comprehensive approach that may include non-pharmacological interventions and should be regularly reassessed for efficacy and ongoing necessity.

Sublingual zolpidem in early onset of sleep compared to oral zolpidem: polysomnographic study in patients with primary insomnia

Randomized Controlled Trial

. 2010 Jun;26(6):1423-31.

doi: 10.1185/03007991003788225.

Corinne Staner 
1
, Frédéric Joly, Nathalie Jacquot, Irina D Vlasova, Maria Nehlin, Thomas Lundqvist, Charlotte Edenius, Luc Staner

Affiliations

Affiliation

  • 1 Forenap Pharma, Rouffach, France.

  • PMID:

    20397964

  • DOI:

    10.1185/03007991003788225

Randomized Controlled Trial

Corinne Staner et al.

Curr Med Res Opin.

2010 Jun.

. 2010 Jun;26(6):1423-31.

doi: 10.1185/03007991003788225.

Authors

Corinne Staner 
1
, Frédéric Joly, Nathalie Jacquot, Irina D Vlasova, Maria Nehlin, Thomas Lundqvist, Charlotte Edenius, Luc Staner

Affiliation

  • 1 Forenap Pharma, Rouffach, France.

  • PMID:

    20397964

  • DOI:

    10.1185/03007991003788225

Abstract


Objective:

To compare the hypnotic effects of a single dose of a sublingual formulation of zolpidem (Edluar*) 10 mg vs oral formulation (Ambien dagger ) 10 mg by polysomnography (PSG) in DSM-IV primary insomnia patients. Primary objective was to compare the two formulations on sleep induction, measured by latency to persistent sleep (LPS), sleep onset latency (SOL) and latency to stage 1 (ST1L).


Research and methods:

This was a randomized, double-blind, two-period, cross-over multi-centre study in which each period comprised two successive PSG recording nights. Treatment was administered when PSG recordings started. Subjective sleep and residual effects were assessed the next morning.


Results:

Seventy female and male patients aged 19-64 were analysed. Sublingual zolpidem significantly shortened LPS by 34% or 10.3 minutes as compared to oral zolpidem (95% CI: -4.3 min to -16.2 min, p = 0.001). SOL and ST1L were also significantly shortened (p < 0.01). Furthermore the two formulations were comparable in terms of sleep maintenance properties based on total sleep time (TST). The improvement in subjective sleep and next-day residual effects did not differ between the two treatments. Both routes of administration were well tolerated.


Conclusions:

The results demonstrate that sublingual zolpidem is superior to an equivalent dose of oral zolpidem in terms of sleep inducing properties in a carefully selected sample of primary insomnia patients.

Similar articles

  • Sublingual zolpidem (Edluar™; Sublinox™).

    Yang LP, Deeks ED.

    Yang LP, et al.
    CNS Drugs. 2012 Nov;26(11):1003-10. doi: 10.1007/s40263-012-0009-y.
    CNS Drugs. 2012.

    PMID: 23034583

    Review.

  • Sublingual zolpidem is more effective than oral zolpidem in initiating early onset of sleep in the post-nap model of transient insomnia: a polysomnographic study.

    Staner L, Eriksson M, Cornette F, Santoro F, Muscat N, Luthinger R, Roth T.

    Staner L, et al.
    Sleep Med. 2009 Jun;10(6):616-20. doi: 10.1016/j.sleep.2008.06.008. Epub 2008 Nov 8.
    Sleep Med. 2009.

    PMID: 18996742

    Clinical Trial.

  • Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia.

    Roth T, Soubrane C, Titeux L, Walsh JK; Zoladult Study Group.

    Roth T, et al.
    Sleep Med. 2006 Aug;7(5):397-406. doi: 10.1016/j.sleep.2006.04.008. Epub 2006 Jul 3.
    Sleep Med. 2006.

    PMID: 16815744

    Clinical Trial.

  • Lower doses of sublingual Zolpidem are more effective than oral Zolpidem to anticipate sleep onset in healthy volunteers.

    Valente KD, Hasan R, Tavares SM, Gattaz WF.

    Valente KD, et al.
    Sleep Med. 2013 Jan;14(1):20-3. doi: 10.1016/j.sleep.2012.09.003. Epub 2012 Dec 4.
    Sleep Med. 2013.

    PMID: 23218533

    Clinical Trial.

  • A new sublingual formulation of zolpidem for the treatment of sleep-onset insomnia.

    Staner L, Danjou P, Luthringer R.

    Staner L, et al.
    Expert Rev Neurother. 2012 Feb;12(2):141-53. doi: 10.1586/ern.11.197.
    Expert Rev Neurother. 2012.

    PMID: 22288669

    Review.

See all similar articles

Cited by

  • Sublingual and oral zolpidem for insomnia disorder: a 3-month randomized trial.

    Castro LS, Otuyama LJ, Fumo-Dos-Santos C, Tufik S, Poyares D.

    Castro LS, et al.
    Braz J Psychiatry. 2020 Apr;42(2):175-184. doi: 10.1590/1516-4446-2019-0389. Epub 2019 Dec 20.
    Braz J Psychiatry. 2020.

    PMID: 31859791
    Free PMC article.

    Clinical Trial.

  • Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline.

    Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL.

    Sateia MJ, et al.
    J Clin Sleep Med. 2017 Feb 15;13(2):307-349. doi: 10.5664/jcsm.6470.
    J Clin Sleep Med. 2017.

    PMID: 27998379
    Free PMC article.

  • Development of a Novel Oral Cavity Compartmental Absorption and Transit Model for Sublingual Administration: Illustration with Zolpidem.

    Xia B, Yang Z, Zhou H, Lukacova V, Zhu W, Milewski M, Kesisoglou F.

    Xia B, et al.
    AAPS J. 2015 May;17(3):631-42. doi: 10.1208/s12248-015-9727-7. Epub 2015 Feb 26.
    AAPS J. 2015.

    PMID: 25716146
    Free PMC article.

  • Sublingual zolpidem (Edluar™; Sublinox™).

    Yang LP, Deeks ED.

    Yang LP, et al.
    CNS Drugs. 2012 Nov;26(11):1003-10. doi: 10.1007/s40263-012-0009-y.
    CNS Drugs. 2012.

    PMID: 23034583

    Review.

Publication types

MeSH terms

Substances

Sublingual zolpidem (Edluar™; Sublinox™) – PubMed

Review

. 2012 Nov;26(11):1003-10.

doi: 10.1007/s40263-012-0009-y.

Lily P H Yang 
1
, Emma D Deeks

Affiliations

Affiliation

  • PMID:

    23034583

  • DOI:

    10.1007/s40263-012-0009-y

Review

Lily P H Yang et al.

CNS Drugs.

2012 Nov.

. 2012 Nov;26(11):1003-10.

doi: 10.1007/s40263-012-0009-y.

Authors

Lily P H Yang 
1
, Emma D Deeks

Affiliation

  • PMID:

    23034583

  • DOI:

    10. 1007/s40263-012-0009-y

Abstract

Zolpidem is a non-benzodiazepine hypnotic used in the short-term treatment of insomnia. A sublingual orally disintegrating tablet formulation of zolpidem (Edluar™; Sublinox™) has been developed to provide a more rapid onset of action than oral immediate-release zolpidem. Sublingual zolpidem has demonstrated bioequivalence to oral zolpidem. In a randomized, double-blind, double-dummy, crossover, multi-centre study in adult patients with primary insomnia (n = 70), a single 10-mg dose of sublingual zolpidem significantly reduced latency to persistent sleep (primary endpoint) compared with a single 10-mg dose of oral immediate-release zolpidem. Sleep-onset latency and latency to stage 1 sleep were also significantly shorter with sublingual zolpidem than with oral zolpidem. Moreover, compared with the oral formulation, sublingual zolpidem was noninferior in terms of total sleep time and did not significantly differ in terms of duration of wake after sleep onset. Sublingual zolpidem was generally well tolerated in this trial, with most adverse events being of mild or moderate severity. The overall tolerability profile of sublingual zolpidem was similar to that of oral zolpidem.

Similar articles

  • A new sublingual formulation of zolpidem for the treatment of sleep-onset insomnia.

    Staner L, Danjou P, Luthringer R.

    Staner L, et al.
    Expert Rev Neurother. 2012 Feb;12(2):141-53. doi: 10.1586/ern.11.197.
    Expert Rev Neurother. 2012.

    PMID: 22288669

    Review.

  • Novel sublingual low-dose zolpidem tablet reduces latency to sleep onset following spontaneous middle-of-the-night awakening in insomnia in a randomized, double-blind, placebo-controlled, outpatient study.

    Roth T, Krystal A, Steinberg FJ, Singh NN, Moline M.

    Roth T, et al.
    Sleep. 2013 Feb 1;36(2):189-96. doi: 10.5665/sleep.2370.
    Sleep. 2013.

    PMID: 23372266
    Free PMC article.

    Clinical Trial.

  • Sublingual zolpidem in early onset of sleep compared to oral zolpidem: polysomnographic study in patients with primary insomnia.

    Staner C, Joly F, Jacquot N, Vlasova ID, Nehlin M, Lundqvist T, Edenius C, Staner L.

    Staner C, et al.
    Curr Med Res Opin. 2010 Jun;26(6):1423-31. doi: 10.1185/03007991003788225.
    Curr Med Res Opin. 2010.

    PMID: 20397964

    Clinical Trial.

  • Low-dose sublingual zolpidem tartrate is associated with dose-related improvement in sleep onset and duration in insomnia characterized by middle-of-the-night (MOTN) awakenings.

    Roth T, Hull SG, Lankford DA, Rosenberg R, Scharf MB; Intermezzo Study Group.

    Roth T, et al.
    Sleep. 2008 Sep;31(9):1277-84.
    Sleep. 2008.

    PMID: 18788653
    Free PMC article.

    Clinical Trial.

  • Zolpidem’s use for insomnia.

    Monti JM, Spence DW, Buttoo K, Pandi-Perumal SR.

    Monti JM, et al.
    Asian J Psychiatr. 2017 Feb;25:79-90. doi: 10.1016/j.ajp.2016.10.006. Epub 2016 Oct 12.
    Asian J Psychiatr. 2017.

    PMID: 28262178

    Review.

See all similar articles

References

    1. Int J Clin Pharmacol Ther. 1996 Apr;34(4):178-83

      –

      PubMed

    1. J Clin Psychiatry.